1. Sitagliptin demonstrated the most prominent malignancy-related safety signal among the dipeptidyl peptidase-4 inhibitors studied. Evidence Rating Level: 2 (Good) ...
1. In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) did not significantly affect the risk of dementia ...
1. Early combination therapy with vildagliptin and metformin is associated with improved glycemic durability in the setting of newly diagnosed ...
Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.
